GSK sells anesthetics to Aspen for up to $370 million

LONDON (Reuters) - GlaxoSmithKline is to sell its portfolio of anesthetic drugs to South Africa's Aspen Pharmacare for up to 280 million pounds ($372 million) as part of a drive by the British drugmaker to focus on core therapy areas.